Beijing Hotgen Biotech Co., Ltd.

Beijing Hotgen Biotech Co., Ltd. saw a significant decline in its stock today, contrasting with broader market trends. The company has faced ongoing challenges, including negative results for 12 consecutive quarters and a notable drop in net sales. Its financial metrics indicate concerns regarding stability and growth prospects.

Beijing Hotgen Biotech Co., Ltd. saw a significant decline in its stock today, contrasting with the broader market. The company has faced ongoing challenges, including a decrease in net sales and negative results over the past 12 quarters, leading to a notable drop in year-to-date performance despite previous annual gains.

Beijing Hotgen Biotech Co., Ltd. saw a notable decline in its stock today, contrasting with the broader market's slight decrease. Over the past month, the company has faced challenges, including a drop in net sales and ongoing negative results, raising concerns about its financial health and operational performance.

Beijing Hotgen Biotech Co., Ltd. saw its stock rise significantly today, contrasting with the modest gain of the China Shanghai Composite index. While the company has shown strong annual growth, it faces challenges such as declining net sales and a history of negative results over the past three years.

Beijing Hotgen Biotech Co., Ltd. saw a notable rise on March 5, 2026, contrasting with a decline in the China Shanghai Composite. Despite impressive annual growth, the company has faced challenges with negative results over the past year and a significant drop in net sales and profit. Its market capitalization is CNY 12,588 million.

Beijing Hotgen Biotech Co. faced a notable stock decline, reflecting ongoing challenges within the company. Despite a substantial yearly increase, the firm has reported negative results for 12 consecutive quarters, with declining net sales and a significant drop in net profit, indicating persistent financial difficulties.